The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Allergan is recalling BIOCELL textured breast implants and tissue expanders due to the potential risk for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The move to recall was based on an analysis of medical device reports submitted to the Food and Drug Administration (FDA) related to BIA-ALCL and BIA-ALCL-related deaths associated with these devices. “Once…
In a clinical trial involving patients with CLL (N=312) or SLL (N=7), median progression-free survival (PFS) was 16.4 months for patients treated with duvelisib vs 9.1 months for those treated with ofatumumab.
This first-in-class drug was previously granted Orphan Drug designation for the treatment of pancreatic cancer, acute myeloid leukemia, Burkitt lymphoma, and myelodysplastic syndromes.
Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence.
Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.
FDA approval was based on positive results from the Phase 3 ECHELON-1 trial.
This slideshow reviews drug information for Yescarta. Click here for the complete Yescarta new product monograph. For a downloadable PDF of this slideshow, click here.
Acalabrutinib is a small-molecule inhibitor of BTK.
Yescarta, a CD19-directed genetically modified autologous T cell immunotherapy, is indicated for use in large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
